AstraZeneca Presents Imfinzi (durvalumab) Plus tremelimumab Combination Data at AACR Annual Meeting

World News: . []

Phase Ib Study 006 long-term follow-up shows clinical activity in PD-L1 greater than or equal to 25 and less than 25 groups in 2nd-line non-small cell lung cancer Phase I Study 10 data shows clinical activity with combination treatment in 2 nd-line...

More news and information about AstraZeneca

Published By:

Thomson Reuters: 22:39 GMT Monday 16th April 2018

Published: .

Search for other references to "astrazeneca" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us
 

Advertising on SPi News: Information For Advertisers